Shezad Malik Law Firm Dr Shezad Malik Law Firm has offices based in Fort Worth and Dallas and represents people who have suffered catastrophic and serious personal injuries including wrongful death, caused by the negligence or recklessness of others. We specialize in Personal Injury trial litigation and focus our energy and efforts on those we represent.

Articles Tagged with Janumet

Pancreatic Cancer Lawsuits Over Januvia, Byetta, and Victoza moving again. Byetta, Januvia, and Victoza lawsuits are back on track over Pancreatic Cancer claims with the recent Ninth Circuit Court of Appeals rulings.

Pancreatic Cancer Lawsuits Over Januvia, Byetta, and Victoza

Pancreatic Cancer Lawsuits Over Januvia, Byetta, and Victoza moving again. Byetta, Januvia, and Victoza lawsuits are back on track over Pancreatic Cancer claims with the recent Ninth Circuit Court of Appeals rulings.

The federal appeals court reactivated more than 750 Byetta, Januvia, Janumet, and Victoza lawsuits brought by folks diagnosed with pancreatic cancer, from the use of these medications.

In the federal court system, a Multidistrict Litigation (MDL) has been established to centralize Byetta, Januvia, Janumet and Victoza pancreatic cancer lawsuits filed in U.S. District Courts by the users of these diabetic drugs.

There are currently at least 262 cases consolidated as part of an MDL, before U.S. District Judge Battaglia in the Southern District of California. Next discovery and pretrial proceedings will proceed, and bellwether trials will be scheduled, probably some time in 2015.

All Byetta, Januvia, Janumet and Victoza cancer lawsuits are consolidated and centralized as part of an MDL, or Multidistrict Litigation.

These product liability cases involve pancreatic cancer after the use of Byetta, Januvia, Janumet or Victoza as part of the “Incretin Mimetics Product Liability Litigation.”

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has agreed to consolidate all Byetta, Januvia, Janumet and Victoza cancer lawsuits, centralizing the litigation as part of an MDL, or Multidistrict Litigation. The JPML issued a Transfer Order on August 26, and these product liability cases involve pancreatic cancer after the use of Byetta, Januvia, Janumet or Victoza as part of the “Incretin Mimetics Product Liability Litigation.”

Januvia Pancreatic Cancer AttorneyThe product liability cases will be centralized before U.S. District Judge Battaglia in the Southern District of California for coordinated handling during pretrial proceedings. The consolidation is beneficial for all parties in complex pharmaceutical litigation, to reduce repetative discovery and to prevent conflicting rulings from different federal judges.

What are Incretin Mimetics?

According to the FDA, there is no scientific evidence to confirm that a group of type 2 diabetes drugs called GLP-1 inhibitors is linked to pancreatic cancer. The FDA decision comes on the heels of the European Medicines Agency, which stated that they have been unable to confirm an increased risk of pancreatic cancer linked to side effects of Byetta, Januvia, Janumet, Victoza and other incretin mimetic drugs.

Januvia Pancreatic Cancer AttorneyThe FDA has apparently completed its safety review into the new group of medications, known as incretin mimetics, and is preparing to report that it has found no conclusive connection between the medications and pancreatic cancer. According to the EMA, its experts reviewed the data and found “methodological limitations and potential sources of bias” and decided the available data don’t bear out worries about an increased risk of “pancreatic adverse events.”

The report addresses the entire group of incretin mimetics, which comprises GLP-1 agonists, which mimic a key hormone, and DPP-4 inhibitors, which interfere with a protein that breaks down the same hormone.

The National Institutes of Health held a workshop, addressing the risks associated with the newer diabetic drugs. These medications, known as Incretic Mimetics are coming under fire for alleged increased risk of pancreatic cancer.

fort_worth_personal_injury_attorney-2.jpg
Merck & Co., Novo Nordisk A/S and others, the manufacturers of these drugs may be asked to collect more data on a potential cancer link even as they try to reassure U.S. regulators this week of the drugs’ safety.

The Food and Drug Administration said it is considering setting up a study, either through the agency or the companies, that looks deeper into whether medicines for Type 2 diabetes, including Merck’s Januvia and Bristol Myers-Squibb Co.’s Byetta, cause pancreatic cell growth that could turn cancerous.

Contact Information